Released Nov 16, 2026, after the close
10-Q filed Nov 16, 2026, 47 days after period end · 0001837607-26-000089
As of November 16, 2026, the Company had received approximately $6.2 million in gross proceeds from exercises of these warrants, providing additional capital to support the continued advancement of the ABP-450 development program.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Net Income | $2.47M | -$4.54M | -$6.17M | -$297.71M |
| EPS Diluted | $0.01 | -$0.39 |
AEON Biopharma, Inc. · CIK 1837607 · Engraved from SEC EDGAR
| -$11.24 |
| $1.35 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
AEON Biopharma received approximately $6.2 million in gross proceeds from exercises of two-year milestone warrants, and their expiration date was accelerated to November 16, 2026.¶2¶1
On November 2, 2026, the Company reduced the exercise price of its outstanding two-year milestone warrants from $0.3221 to $0.20 per share of common stock.¶3
The Company reported cash and cash equivalents of $11.4 million as of September 30, 2026, which does not include the warrant proceeds received in the fourth quarter of 2026.¶4
The Company submitted an IND for a comparative CMAP pharmacodynamic study of ABP-450 and BOTOX, with study initiation expected in the first quarter of 2027.¶5¶6
The Company reported expanded structural data with approximately 98% coverage of the core neurotoxin sequence and 100% amino acid identity across all regions analyzed.¶7¶8